Peptídeos

A synthetic peptide for use as a blocking control in assays to test for specificity of FZD2 antibody, catalog no. 70R-7184

A synthetic peptide for use as a blocking control in assays to test for specificity of KLHDC8B antibody, catalog no. 70R-3775

Bovine Serum Albumin (BSA) is a protein that is used in the pharmaceutical industry as a research tool and an immunological reagent. BSA can be used to bind, stabilize, and prevent denaturation of other proteins in the laboratory. It has been shown to inhibit ion channels and ligand-gated ion channels, which are important for membrane potentials. BSA is also an activator of receptor tyrosine kinases, which are involved in cell signaling pathways.

Antipain is a proteolytic enzyme that hydrolyzes peptide bonds in proteins. It is a member of the papain family of proteases and has been shown to activate peptides and inhibit ion channels, both of which are important for cell biology research. Antipain, an inhibitor of protein synthesis, is also used as a research tool in cell biology and biochemistry.

A synthetic peptide for use as a blocking control in assays to test for specificity of BCO2 antibody, catalog no. 70R-10117

A synthetic peptide for use as a blocking control in assays to test for specificity of Cyb5r1 antibody, catalog no. 70R-8676

A synthetic peptide for use as a blocking control in assays to test for specificity of RNF5 antibody, catalog no. 70R-9592

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP24A1 antibody, catalog no. 70R-9999

A synthetic peptide for use as a blocking control in assays to test for specificity of CHIA antibody, catalog no. 70R-5921

A synthetic peptide for use as a blocking control in assays to test for specificity of EIF3H antibody, catalog no. 70R-8910

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC14A1 antibody, catalog no. 70R-7059

A synthetic peptide for use as a blocking control in assays to test for specificity of TTC27 antibody, catalog no. 70R-9467

Sarafotoxin S6b, sourced from the venom of the Atractaspis engaddensis snake family, is one of four (S6a-d) isopeptides of the Sarafotoxins. This product is a synthetically produced toxin, containing disulfide bonds between Cys1-Cys15 and Cys3-Cys11.Due to their structural and functional homology to the endothelin peptides, Sarafotoxins can enhance vasoconstriction through stimulating the class A G-protein-coupled, endothelin ETA and ETB receptors. This in turn leads to left ventricular dysfunction and bronchoconstriction.
As the most potent Sarafotoxin, sarafotoxin S6b binds to both ETA and ETB receptors with a similar affinity to Endothelin-1. This is evident as when given to mice intravenously, sarafotoxin S6b caused cardiac arrest and death in mice almost immediately. Additional characteristics of S6b is its matrix metalloproteinase inhibitory activity due to it exhibiting a fold which is also found in the core region of tissue inhibitors of metalloproteinases (TIMPs).
Sarafotoxin S6b can be used as a pharmacological reagent to study the interactions of Endothelins and their corresponding receptors. This product is available as a 0.1mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of MFN1 antibody, catalog no. 70R-4467

A synthetic peptide for use as a blocking control in assays to test for specificity of FCN3 antibody, catalog no. 70R-5456

A synthetic peptide for use as a blocking control in assays to test for specificity of CGB antibody, catalog no. 70R-9986

A synthetic peptide for use as a blocking control in assays to test for specificity of CANT1 antibody, catalog no. 70R-5814

The LRG1 Blocking Peptide is a highly effective monoclonal antibody that acts as a phosphatase inhibitor in Life Sciences research. This neutralizing peptide is widely used in the field of monoclonal antibodies and has been proven to effectively block the activity of LRG1, a glycoprotein involved in various biological processes.

A synthetic peptide for use as a blocking control in assays to test for specificity of ASXL2 antibody, catalog no. 70R-3526

A synthetic peptide for use as a blocking control in assays to test for specificity of STAT5B antibody, catalog no. 20R-1134

A synthetic peptide for use as a blocking control in assays to test for specificity of ITGB3BP antibody, catalog no. 70R-6093

A synthetic peptide for use as a blocking control in assays to test for specificity of SLCO3A1 antibody, catalog no. 70R-6586

1-Deoxyfructosyl-Val-His (1DFVH) is a research tool that belongs to the group of activators. It has been shown to activate receptors and ion channels, as well as inhibit antibody production. 1DFVH also has an effect on cell biology, which may be due to its ability to interact with proteins in a variety of ways. 1DFVH binds to the receptor by competitive inhibition and activates the receptor by mimicking the natural ligand. This compound has been shown to activate ion channels in cells through the opening of potassium channels, leading to depolarization and increased calcium influx into cells.

A synthetic peptide for use as a blocking control in assays to test for specificity of DHRSX antibody, catalog no. 70R-7875

A synthetic peptide for use as a blocking control in assays to test for specificity of NSMCE1 antibody, catalog no. 70R-2769

A synthetic peptide for use as a blocking control in assays to test for specificity of RBJ antibody, catalog no. 70R-5875

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM120C antibody, catalog no. 70R-10170

A synthetic peptide for use as a blocking control in assays to test for specificity of FAAH2 antibody, catalog no. 70R-7541

A synthetic peptide for use as a blocking control in assays to test for specificity of SPTAN1 antibody, catalog no. 70R-2207

A synthetic peptide for use as a blocking control in assays to test for specificity of WT1 antibody, catalog no. 70R-8233

A synthetic peptide for use as a blocking control in assays to test for specificity of RAB18 antibody, catalog no. 70R-5796

A synthetic peptide for use as a blocking control in assays to test for specificity of GMFG antibody, catalog no. 70R-6206

A synthetic peptide for use as a blocking control in assays to test for specificity of PPM1B antibody, catalog no. 70R-2682

A synthetic peptide for use as a blocking control in assays to test for specificity of LONRF3 antibody, catalog no. 70R-2616

A synthetic peptide for use as a blocking control in assays to test for specificity of C2orf25 antibody, catalog no. 70R-4055

A synthetic peptide for use as a blocking control in assays to test for specificity of CST9 antibody, catalog no. 70R-6727

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC22A6 antibody, catalog no. 70R-7524

A synthetic peptide for use as a blocking control in assays to test for specificity of DCTN4 antibody, catalog no. 70R-3016

A synthetic peptide for use as a blocking control in assays to test for specificity of GPHN antibody, catalog no. 70R-2208

Bombesin is a small peptide that was first isolated from the skin of a frog, Bombina bombina, with homologs later found to be present in mammalian tissues, including the brain and gastrointestinal tract. It is a member of the bombesin-like peptide family, which includes several related peptides such as gastrin-releasing peptide (GRP) and neuromedin B.
Bombesin acts as a neuromodulator and regulates various physiological functions, including gastrointestinal motility and stimulation of gastrin release from G cells. It also plays a role in the regulation of cardiovascular function and neurotransmitter release. In addition, bombesin has been shown to stimulate the growth and proliferation of certain types of cancer cells, including prostate and lung cancer cells, through its interaction with bombesin receptors. It may therefore be used as a potential biomarker for certain cancers.

A synthetic peptide for use as a blocking control in assays to test for specificity of LCN12 antibody, catalog no. 70R-5485

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Extraordinary strength of the streptavidin-biotin interaction allows for efficient capturing of even highly dilute targets; however, it makes recovery of proteins from affinity resins challenging. Conventional methods to elute biotinylated proteins from immobilized avidin include the following: (i) denaturation of streptavidin by boiling the resin in a denaturing buffer that may include high concentrations of chaotropic salts, (ii) trypsin digestion of proteins while they are bound to the resin, or (iii) elution of proteins with excess free biotin. These protocols can co-elute contaminant proteins by releasing nonspecifically bound proteins and/or naturally biotinylated proteins concurrently with labeled proteins. In addition, some of these methods can cause elution of high levels of resin-based peptides along with the proteins of interest, resulting in further sample contamination.
Disulfide Biotin Azide probe eliminates a major limitation of the streptavidin-biotin affinity purification. This reagent contains a biotin moiety linked to an azide moiety through a spacer arm containing a cleavable disulfide linker. Captured biomolecules can be efficiently released under mild conditions (50 mM dithiothreitol, 10 mM 2-mercaptoethanol or 1% sodium borohydride) and the small molecular fragment (188.25 Da) left on the labeled protein following cleavage. These features make the cleavable probe especially attractive for use in biomolecular labeling and proteomic studies.

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity